SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

	MINERALYS THERAPEUTICS, INC.
	(Name of Issuer)
	Common Stock
	(Title of Class of Securities)
	000470404
	603170101
	(CUSIP Number)
	Abrar Hussain
	Samsara BioCapital GP, LLC, 628 Middlefield Road Palo Alto, CA, 94301 (650) 285-4270
(Name, Address	s and Telephone Number of Person Authorized to Receive Notices and Communications
	09/04/2025

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. \square

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.	603170101
-----------	-----------

4	Name of reporting person	
1	Samsara BioCapital, L.P.	
2	Check the appropriate box if a member of a Group (See Instructions) (a) (b)	
3	SEC use only	
4	Source of funds (See Instructions)	
4	wc	

5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
6	Citizenship or place of organization DELAWARE	
	7	Sole Voting Power 0.00
Number of Shares Benefici	8	Shared Voting Power 5,674,916.00
ally Owned by Each Reporti	9	Sole Dispositive Power 0.00
ng Person With:	10	Shared Dispositive Power 5,674,916.00
11	Aggregate amount beneficially owned by each reporting person 5,674,916.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
13	Percent of class represented by amount in Row (11) 7.3 %	
14	Type of Reporting Person (See Instructions) PN	

CUSIP No. 603170101

1	Name of reporting person Samsara BioCapital GP, LLC
2	Check the appropriate box if a member of a Group (See Instructions) (a) (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE

Number of	7	Sole Voting Power
		0.00
Shares Benefici	8	Shared Voting Power
ally Owned		5,674,916.00
by Each Reporti	9	Sole Dispositive Power
ng Person		0.00
With:	40	Shared Dispositive Power
	10	5,674,916.00
	Aggregate amount beneficially owned by each reporting person	
11	5,674,916.00	
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
12		
40	Percent of class represented by amount in Row (11)	
13	7.3 %	
44	Type of Reporting Person (See Instructions)	
14	00	

CUSIP No. 603170101

1	Name of reporting person Samsara Opportunity Fund, L.P.	
2	Check the appropriate box if a member of a Group (See Instructions) (a) (b)	
3	SEC use only	
4	Source of funds (See Instructions) WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
6	Citizenship or place of organization DELAWARE	
Number of	7	Sole Voting Power 0.00
Shares Benefici ally Owned	8	Shared Voting Power 588,235.00
by Each Reporti ng Person With:	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 588,235.00
ſ .		

11	Aggregate amount beneficially owned by each reporting person 588,235.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.8 %
14	Type of Reporting Person (See Instructions) PN

CUSIP No. 603170101

	Name of reporting person		
1	Name of reporting person		
	Samsara Opportunity Fund GP, LLC		
2	Check the appropriate box if a member of a Group (See Instructions)		
3	SEC use	only	
4	Source of funds (See Instructions)		
4	AF		
	Check if o	disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
5	Electric disconduction of logar processings to required parediant to its me 2(a) or 2(e)		
	Citizensh	in or place of organization	
6	Citizenship or place of organization DELAWARE		
	DELAWA	<u></u>	
	7	Sole Voting Power	
Number	'	0.00	
of Shares		Shared Voting Power	
Benefici ally	8	588,235.00	
Owned by Each	9	Sole Dispositive Power	
Reporti		0.00	
ng Person			
With:	10	Shared Dispositive Power	
		588,235.00	
	Aggregat	e amount beneficially owned by each reporting person	
11	588,235.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
13	Percent of class represented by amount in Row (11)		
	0.8 %		
	Type of Reporting Person (See Instructions)		
14	00		

CUSIP No. 603170101

1	Name of reporting person		
	Srinivas Akkaraju Chaek the annuaniste havifa manhar of a Craum (See Instructions)		
2	Check the appropriate box if a member of a Group (See Instructions) (a) (b)		
3	SEC use	only	
4	Source of funds (See Instructions) AF		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
6	Citizenship or place of organization UNITED STATES		
Number	7	Sole Voting Power 83,043.00	
of Shares Benefici ally Owned	8	Shared Voting Power 6,263,151.00	
by Each Reporti ng Person	9	Sole Dispositive Power 83,043.00	
With:	10	Shared Dispositive Power 6,263,151.00	
11	Aggregate amount beneficially owned by each reporting person 6,346,194.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
13	Percent of class represented by amount in Row (11) 8.2 %		
14	Type of Reporting Person (See Instructions) IN		

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock

(b) Name of Issuer:

MINERALYS THERAPEUTICS, INC.

(c) Address of Issuer's Principal Executive Offices:

150 N. Radnor Chester Road, Suite F200, Radnor, PENNSYLVANIA, 19087.

Item 1 Comment:

This Amendment No. 3 (this "Amendment No. 3" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on February 24, 2023, and amended on February 12, 2024 and March 17, 2025 (as amended, the "Statement") by Samsara LP, Samsara GP and Dr. Akkaraju. Unless otherwise defined herein, capitalized terms used in this Amendment No. 3 shall have the meanings ascribed to the min the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

Item 2. Identity and Background

- (a) This Schedule 13D is being filed on behalf of This Schedule 13D is filed by Samsara BioCapital, L.P. ("Samsara LP"), Samsara BioCapital GP, LLC ("Samsara GP"), Samsara Opportunity Fund, L.P. ("Samsara Opp LP") Samsara Opportunity Fund GP, LLC ("Samsara Opp GP") and Dr. Srinivas Akkaraju ("Dr. Akkaraju"). Samsara LP, Samsara GP, Samsara Opp LP, Samsara Opp GP and Dr. Akkaraju are collectively referred to herein as the "Reporting Persons." The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, (the "Act") is attached hereto as Exhibit 99.1.
- (b) The address of the principal business office of each of the Reporting Persons is 628 Middlefield Road, Palo Alto, CA 94301.
- (c) The principal business of the Reporting Persons is venture capital investments. Dr. Akkaraju serves as the Managing Member of e ach of Samsara GP, which is the general partner of Samsara LP, and Samsara Opp GP, which is the general partner of Samsara Opp LP.
- (d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
- (e) During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial of administrative body of competent jurisdiction or were subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating a ctivities subject to, federal or state securities laws or finding any violation with respect to such laws.
- (f) Each of Samsara LP, Samsara GP, Samsara Opp LP and Samsara Opp GP was organized in the state of Delaware and Dr. Akka raju is a citizen of the United States.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Statement is hereby amended and supplemented as follows:

On September 4, 2025, Samsara Opp LP purchased 588,235 shares of common stock at a price of \$25.50 per share from the und erwriters of the Issuer's public offering (the "September 2025 Offering"). The aggregate purchase price for all securities acquired by Samsara Opp LP in the September 2025 Offering was \$14,999,993, which was funded by short-term borrowing from Samsara L P.

Item 5. Interest in Securities of the Issuer

Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of: (i) 66,295,184 shares of common stock outstanding as of August 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025 and (ii) 11, 274,509 shares of common stock issued in the September 2025 Offering as disclosed in the Issuer's prospectus supplement date d September 2, 2025 filed with the SEC on September 3, 2025; and (iii) with respect to Dr. Akkaraju, 83,043 shares of common st ock issuable upon the exercise of stock options within 60 days.

The Reporting Persons' ownership of the Issuer's securities consists of (i) 5,674,916 shares of common stock directly held by Samsara LP; (ii) 588,235 shares of common stock directly held by Samsara Opp LP; (iii) a total of 75,116 vested stock options (right to buy) held by Dr. Akkaraju; and (iv) 7,927 stock options (right to buy) scheduled to vest within 60 days of this filing held by Dr. Akkaraju.

Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Sams ara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP.

Samsara Opp GP is the sole general partner of Samsara Opp LP and Dr. Akkaraju is the managing member of Samsara Opp GP. Each of Samsara Opp GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsar a Opp LP.

- (b) Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
- (c) Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.
- (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the securities beneficially owned by any of the Reporting Persons.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of the Statement is hereby amended and supplemented as follows:

Lock-up Agreement

Each of the Issuer's executive officers and directors, including Dr. Akkaraju, have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 60 days from September 2, 2 025 without first obtaining the written consent of BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs & Co. LLC, subj ect to specified exceptions, including sales pursuant to existing trading plans established under Rule 10b5-1 under the Exchange Act.

The foregoing description of the Lock-up Agreement is not complete and is qualified in its entirety by reference to the full text of the form of the lock-up agreement attached hereto as Exhibit 99.2 and incorporated by reference herein.

Material to be Filed as Exhibits. Item 7.

Exhibit 99.1 Joint Filing Agreement

Exhibit 99.2 Form of Lock-up From Directors and Officers (incorporated by reference to Exhibit A to the Underwriting Agreement fil ed as Exhibit 1.1 to the Issuer's Current Report on Form 8-K, filed with the SEC on September 3, 2025).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Samsara BioCapital, L.P.

Signature: /s/ Srinivas Akkaraju

Name/Title: By Samsara BioCapital GP, LLC, its General Partner,

By Srinivas Akkaraju, Managing Member

09/08/2025 Date:

Samsara BioCapital GP, LLC

Signature: /s/ Srinivas Akkaraju

Name/Title: By Srinivas Akkaraju, Managing Member

Date: 09/08/2025

Samsara Opportunity Fund, L.P.

Signature: /s/ Srinivas Akkaraju

By Samsara Opportunity Fund GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member Name/Title:

Date: 09/08/2025

Samsara Opportunity Fund GP, LLC

Signature: /s/ Srinivas Akkaraju

Name/Title: By Srinivas Akkaraju, Managing Member

Date: 09/08/2025

Srinivas Akkaraju

Signature: /s/ Srinivas Akkaraju Name/Title: Srinivas Akkaraju

Date: 09/08/2025

EXHIBIT 99.1

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the Schedule 13D (or any amendments thereto) relating to the common stock of Mineralys Therapeutics, Inc. is filed on behalf of each of us.

Dated: September 8, 2025

Samsara BioCapital, L.P.

By: Samsara BioCapital GP, LLC

its General Partner

By: <u>/s/ Srinivas Akkaraju</u> Name: Srinivas Akkaraju Title: Managing Member

Samsara BioCapital GP, LLC

By: /s/ Srinivas Akkaraju Name: Srinivas Akkaraju Title: Managing Member

Samsara Opportunity Fund, L.P.

By: Samsara Opportunity Fund GP, LLC

its General Partner

By: <u>/s/ Srinivas Akkaraju</u> Name: Srinivas Akkaraju Title: Managing Member

Samsara Opportunity Fund GP, LLC

By: /s/ Srinivas Akkaraju Name: Srinivas Akkaraju Title: Managing Member

/s/ Srinivas Akkaraju Srinivas Akkaraju